MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trialOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.